Key points from article :
Nanoscope Therapeutics' gene therapy (MCO-010) uses light-sensitive molecules to treat vision loss from retinal diseases.
Phase 2b study showed improvement in vision for patients with advanced retinitis pigmentosa (RP).
Statistically significant improvement in visual acuity was observed after one year.
Therapy was well-tolerated with no serious side effects reported.
Nanoscope plans to apply for FDA approval in the second half of 2024.
MCO-010 targets inner retinal neurons to restore vision unlike other gene therapies targeting specific mutations.
Also testing out for mutation-agnostic gene therapy in Stargardt disease, another rare eye disease.
Trial led by David Boyer from USC Keck School of Medicine.
